logo-loader

Proactive News Summary – Hayward Tyler, Tissue Regenix, Motive TV, Galasys, Tungsten Group, EMED Mining, Savannah Resources, Paragon Diamonds

Published: 17:16 05 May 2015 BST

stock_market_chart_350_5548ed353d675

There were a few signings made by AIM companies. 

British engineering group Hayward Tyler (LON:HAYT) was among a number of notable AIM firms getting deals done today.

It has signed a production alliance agreement with FMC Technologies, the big player in the sub-sea systems, which will see the Luton-based motors and pumps specialist manufacture permanent magnet motors.

FMC will, meanwhile, also commit an initial US$2mln towards the development of Hayward Tyler’s Luton plant.

In other signings, regenerative medicine company Tissue Regenix (LON:TRX) signed a new regional distribution deal worth a minimum US$600,000 in the US TRX Wound Care (Tissue’s US subsidiary) for its DermaPure skin graft product.

TV-on-the-move specialist Motive Television (LON:MTV) signed a bring-your-own-device contract with Attica Group, a Greek ferry firm.

Theme park ticketing specialist Galasys (LON:GLS) appointed a representative from its new substantial shareholder Beijing Shiji to its board. 

Elsewhere, there was also a number of mining companies in the news. Premier African Minerals’ (LON:PREM) process plant for its RHA tungsten project in Zimbabwe is complete and ready for shipment. 

Meanwhile, Tungsten Network, the electronic invoicing platform operated by Tungsten Group (LON:TUNG) has moved south of the border, down Mexico way.

From a company named after a specialist metal to metal recovery specialist, as Rambler Metals’ (LON:RMM) told investors that a copper price recovery and cost cutting has stabilised operations at its Ming Mine in Newfoundland, Canada.

In other copper news, EMED Mining (LON:EMED) said it expects to have sufficient working capital to last until it secures a binding long term financing – which is now expected in a matter of weeks after non-binding terms have been agreed for an equity financing structure with several parties.

Now to gold, where Savannah Resources (LON:SAV) says it has found more strong indications of gold during its exploration programme at Gaddmah West in Oman. 

David Archer, Savannah’s chief executive, said the results appear to be the gold-rich part of a VMS system that bears similarities to the major Rakah gold deposit which was successfully mined in the 1990's. 

In other metal news, African iron junior Ferrum Crescent (LON:FCR) revealed a partial sale deal to advance through the bankable feasibility process at  the Moonlight project in South Africa.

Paragon Diamonds (LON:PRG) has unveiled the £8.5mln acquisition of a diamond mine close to its flagship Lemphane project, notably it is also just five kilometres from Gem Diamonds' (LON:GEM) world-class Letseng operation.

Back in Blighty, UK Oil and Gas (LON:UKOG), the firm behind the Horse Hill discovery near Gatwick, continued to  distance itself from comments made by its chairman David Lenigas. 

There were two nuggets of news out on Chariot Oil & Gas (LON:CHAR) today. First, the company detailed further cost-savings including a 50% cut to director remuneration. Then, it announced that current chief financial officer Mark Reid will leave the company.

From cost-cutting to fundraising - Northcote Energy (LON:NCT) has raised £2.8mln to pursue investment opportunities in Mexico’s previously nationalised energy sector.

Similarly, New World Oil & Gas (LON:NEW) is considering the possibility of launching a rights issue due to increased interest in the group’s shares aftera recent share placing raised £1.5mln and ended its financing arrangements with Yorkville Advisors.

Meanwhile, Tethys Petroleum (LON:TPL, TSE:TPL) said the proposed divestment of Kazakhstan assets to a Chinese buyer will not proceed after the Kazakh ministry of energy failed to approve the transaction before a deadline set by the Chinese group.

In pharma news, stem cell specialist ReNeuron Group (LON:RENE) received the green light to begin its first ever clinical trial in the US.

The Food & Drug Administration has given the go ahead for the use of the AIM-listed group’s human retinal progenitor cell therapy candidate in 15 patients.

US giant Gilead has recorded good progress with two drugs being developed using Abzena’s (LON:ABZA) antibody technology (Antitope), underlining the potential of the AIM-listed pharma according to Cenkos.

In other news, Domino’s Pizza franchisee DP Poland (LON:DPP) said like-for-like sales across its corporate and franchised outlets were 17% higher than last year’s January-March period.

Elsewhere, The Real Good Food Company said non-executive director Peter Salter, purchased 50,000 ordinary shares in the Company at a price of 42.25p per share, taking his stake to 0.26%.

And finally, Forbidden Technologies (LON:FBT) has launched the new branding for its consumer video editor - now branded Captivate.

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

29 minutes ago